Curriculum Vitae

Scott A. Wright, MD, FACC
1783 Troup Hwy, Tyler, Texas 75701
Office (903)-595-2283 Fax (903)-597-2238

Practice

2012-2016	Center for Medical Weight Loss of East Texas, Medical Director 1761 Troup Hwy, Tyler, Texas
2009-Present	Tyler Cardiac and Endovascular Center- 1769 Troup Hwy, Tyler, Texas
2003-Present	Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Affiliation

2003-Present	CAET - Research - 1761 Troup Hwy, Tyler, Texas
1/1/13-4/26/13	TAD Clinical Research - 1741 Troup Hwy, Tyler, Texas

Education

1993-1997	University of Texas Medical Branch at Galveston Galveston, Texas Doctorate of Medicine
1991-1993	University of Texas at Arlington Arlington, Texas Master of Computer Science
1984-1989	Texas A&M University College Station, Texas Bachelor of Science (Major: Bioengineering)

Post-Graduate Training
Cardiology Fellowship

2000-2003	University of Texas Medical Branch at Galveston Galveston, Texas

Internal Medicine Residency

1997-2000	University of Texas Medical Branch at Galveston Galveston, Texas

Board Certification

2004	American Board of Internal Medicine – Cardiovascular Disease
2004	Board Certified in Echocardiography
2004	Board Certified in Nuclear Cardiology

Licensure

2003	Nuclear Radiation Certification State of Texas
2000	Texas State Board of Medical Examiners

Hospital Appointments

CHRISTUS Trinity Mother Frances Hospital, Tyler, Texas

CHRISTUS Trinity Mother Frances Hospital, Jacksonville, Texas

UT Health East Texas (ETMC), Tyler, Texas

UT Health East Texas (ETMC), Athens, Texas

UT Health East Texas (ETMC), Carthage, Texas

UT Health East Texas (ETMC), Jacksonville, Texas

Research

Co-Investigator - FORXIGA-HF - Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction. (D1699C00001)

Co-Investigator - PROVE-HF - A 52 Week, open label evaluation on the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient-reported outcomes in heart failure with reduced left ventricular ejection fraction.

Co-Investigator - CHAMP-HF – Observational Registry of Treatment Patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.

Principle Investigator – CAMELLIA - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

Principle Investigator - ODYSSEY - A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.

Principle Investigator - SUMMIT - HZC113782 A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

Co-Investigator – DECLARE - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.

Co-Investigator – ABSORB III - Randomized Controlled Trial. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native coronary Artery Lesions.

Co-Investigator – AD HOC PCI - A randomized, open-label, multiple-center, parallel group, study to compare the platelet inhibition with Verify Now™ assay of ticagrelor vs. clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)

Co-Investigator – EXCITE - Excimer laser randomized Controlled study for treatment of femoropopliteal In-Stent Restenosis.

Co-Investigator – EUCLID -A randomized, double-blind, parallel group, multicenter phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID – Examining Use of tiCagreLor In paD)

Co-Investigator – PARADIGM - A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction.

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Investigator – MUSIC – Multi-Sensor Monitoring in Congestive Heart Failure Study.

Investigator – RECORD AF – **RE**gistry on **C**ardiac rhythm dis**ORD**ers: an international, observational, prospective survey assessing the control of **A**trial **F**ibrillation.

Co-Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.

Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.

Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.

Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.

Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).

Co-Investigator – VISION 305 Study - "Vasodilator Induced Stress In Concordance with Adenosine" A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.

Co-Investigator - APEX-AMI Study - "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary

Percutaneous Coronary Intervention." (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.

Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

High Frequency Electrocardiograms versus Standard Electrocardiograms in Acute Coronary Syndromes: assessing improved sensitivity of HF-EKG in multiple clinical scenarios including adenosine stress testing, percutaneous interventions, risk stratification in emergency departments. Study done in conjunction with NASA.

Retrospective Analysis of Adenosine Perfusion Studies in Prediction of Coronary Artery Disease: Comparing results of adenosine perfusion studies with documented coronary anatomy by cardiac catheterization.

Masters Thesis, Roger S. Walker, Ph.D. University of Texas at Arlington, Department of Computer Science Developed high resolution laser measurement system for Texas Highway Department.

Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532

Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: Cordarone• I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US

Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE " A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Assess The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease.

Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy "AMIHOT" Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.

Co-Investigator – A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina.

Co-Investigator – Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System